When treating patients with cancer, a critical issue is varied progression rates. Some cancers are aggressive while others are slow growing, making it difficult to decide the best treatment plan and avoid unnecessary treatments. Ataraxis AI is tackling this problem, beginning with breast cancer.
The company has developed an AI-powered diagnostic tool called Ataraxis Breast, which assesses whether a breast cancer is high or low risk. A recent study suggests that the company's system is up to 30% more accurate than the current standard. This allows doctors to make more informed decisions, taking the predicted progression into account.
Founded in 2023, the company is already making impressive strides, emerging from stealth with promising seed funds. Ataraxis AI plans to enhance its tools further and expand its product line into other cancers, with its software made available to healthcare providers by 2025.
Steph
Company Specialist at Welcome to the Jungle